Phase 2 Study of MR13A9.
Phase 2
- Conditions
- Hemodialysis patients with uremic pruritus.
- Registration Number
- JPRN-jRCT2080223210
- Lead Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
(1) Patients with chronic renal failure who regularly receive hemodialysis three times weekly.
(2) Patients who have treated with systemic therapy and topical therapy for itching and not adequately responded to either of them.
(3) Patients who are treating with one or more of the drugs for iching.
(4) Patients with a mean VAS (Visual Analogue Scale) score of >= 50mm.
Exclusion Criteria
Patients who are judged to be inadequate for this study participation by the investigator or the subinvestigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Iching visual analogue scale.
- Secondary Outcome Measures
Name Time Method Shiratori's severity criteria etc.